

Full Paper

Expression of Cytosolic Phospholipase A₂α in Murine C12 Cells, a Variant of L929 Cells, Induces Arachidonic Acid Release in Response to Phorbol Myristate Acetate and Ca²⁺ Ionophores, but Not to Tumor Necrosis Factor-αMasaya Shimizu¹, Chihiro Azuma¹, Tomoko Taniguchi¹, and Toshihiko Murayama^{1,*}¹Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8675, Japan

Received July 12, 2004; Accepted September 27, 2004

Abstract. Tumor necrosis factor-α (TNFα)-induced cell death is regulated through the release of arachidonic acid (AA) by group IVA cytosolic phospholipase A₂ (cPLA₂α) in the murine fibroblast cell line L929. However, the signaling pathway by which TNFα activates cPLA₂α remained to be solved. We examined AA release in L929 cells, in a variant of L929 (C12 cells) lacking cPLA₂α, and in C12 cells transfected with cPLA₂α expression vectors. In transient and stable clones of C12 cells expressing cPLA₂α, Ca²⁺ ionophore A23187 and phorbol myristate acetate (PMA) stimulated AA release within 90 min, although no response to TNFα was observed within 6 h. These results suggest that C12 cells may lack the components necessary for TNFα-induced AA release, in addition to cPLA₂α. PMA is known to stimulate AA release via phosphorylation of Ser⁵⁰⁵ in cPLA₂α by activating extracellular signal-regulated kinases (ERK1/2). However, PMA-induced AA release from C12 cells expressing mutant cPLA₂αS505A (mutation of Ser⁵⁰⁵ to Ala), which is not phosphorylated by ERK1/2, was similar to that from L929 cells and C12 cells expressing wild-type cPLA₂α. The role of Ser⁵⁰⁵ phosphorylation in AA release induced by PMA is also discussed.

Keywords: cytosolic phospholipase A₂α, tumor necrosis factor, Ca²⁺ ionophore, phorbol myristate acetate, L929 and C12 cells

Introduction

Tumor necrosis factor α (TNFα) exerts cytotoxic action against several cells including mouse L929 fibrosarcoma cells and fibroblasts (1–4). TNFα-evoked responses such as cell death (1–3), the accumulation of reactive oxygen species (4, 5), and gene expression (6, 7) are mediated by the activation of phospholipase A₂ (PLA₂) and/or arachidonic acid (AA). Group IVA cytosolic PLA₂ (cPLA₂α) selectively releases AA from the *sn*-2 position of glycerophospholipids (8, 9). The L929 variant C12, which expresses undetectable levels of cPLA₂α, is resistant to TNFα-induced AA release and cell death (1, 2, 10). The C12 cell line was found to be analogous to the parental L929

cell line in all parameters of TNFα receptor binding and internalization, and transfection of C12 cells with cPLA₂α cDNA recovered TNFα-induced AA release and cell death (1, 10). Since TNFα was able to activate nuclear factor κB (NFκB) in both L929 cells and C12 cells (3), functions of the TNFα receptor appears to be intact in C12 cells. Clones of C12 cells expressing cPLA₂α appear to be useful for studying TNFα-induced signaling pathways, particularly the mechanism of cPLA₂α activation. In the present study, we tried to express cPLA₂α protein in C12 cells using two vector systems (pcDNA4/HisMax and pEB6 CAG).

Activation of cPLA₂α is regulated by phosphorylation and Ca²⁺-dependent translocation from the cytosol to membranes (8, 9). The presence of a consensus phosphorylation site for mitogen-activated protein kinase (MAPK) at Ser⁵⁰⁵ of cPLA₂α has led to studies

*Corresponding author. FAX: +81-43-226-2875
E-mail: murayama@p.chiba-u.ac.jp

demonstrating the role of MAPKs including extracellular signal-regulated kinases (ERK1/2) in the phosphorylation and activation of this enzyme (8, 9). One proposed model for TNF α -induced AA release is that stimulation of the TNF α receptor (type 1, p55) causes the activation of a ceramide-activated protein kinase that phosphorylates Raf-1 kinase, which eventually results in the phosphorylation and activation of ERK1/2 (11). ERK1/2 in turn phosphorylates and activates cPLA₂α (8, 9). However, cPLA₂ activation is a necessary component in the pathways leading to TNF α -induced ceramide accumulation in L929 cells (3). Thus, TNF α -induced signaling pathways coupled with activation of cPLA₂α are not fully elucidated. TNF α -induced responses were regulated by a protein kinase C (PKC) pathway (12, 13) and a role for PKC in the regulation of cPLA₂α and AA release has been shown (8, 14, 15). Activation of PKC can trigger a kinase cascade leading to activation of ERK1/2 and the resulting release of AA (8, 15, 16), but the relationship between PKC and the MAPK pathways in AA release is still largely unknown.

In this study, we established two stable C12 cell clones expressing wild-type cPLA₂α and mutant cPLA₂α (Ser⁵⁰⁵ mutation) and examined the release of AA induced by phorbol myristate acetate (PMA), A23187 and TNF α . In stable clones of C12 cells expressing wild-type cPLA₂α, PMA and A23187 stimulated AA release but no response to TNF α was observed. Our findings also suggest that the PMA-induced release was not mediated by phosphorylation of Ser⁵⁰⁵ in cPLA₂α. We discuss the possibility that C12 cells lack the component(s) essential for TNF α -induced AA release in addition to cPLA₂α and the role of Ser⁵⁰⁵ phosphorylation in AA release induced by PMA.

Materials and Methods

Materials

[5,6,8,9,11,12,14,15-³H]AA (214 Ci/mmol, 7.92 TBq/mmol) and 1-palmitoyl-2-[¹⁴C]-arachidonyl phosphatidylcholine (48 mCi/mmol, 1776 MBq/mmol) were purchased from Amersham Bioscience (Buckinghamshire, UK) and Perkin Elmer (Boston, MA, USA), respectively. TNF α was obtained from Pepro Tech EC Ltd. (London, UK). A23187, ionomycin, and PMA were purchased from Sigma (St. Louis, MO, USA). The concentrations of reagents were the same as those in previous reports (14, 17, 18). A23187, ionomycin, and PMA were dissolved in dimethyl sulfoxide, and the final concentration of dimethyl sulfoxide in the medium was under 0.5%. The vehicle containing dimethyl sulfoxide did not stimulate AA release for 6 h.

Cell culture, construction of expression vectors, and isolation of stable clones

L929 cells, C12 cells, and human embryonic kidney (HEK) 293T cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (Thermo Trace Ltd., Noble Park, Australia), 200 U/mL penicillin G sodium, and 200 μ g/mL streptomycin sulfate (10, 19). The pcDNA4/HisMax and pEB6 CAG mammalian expression vectors for human cPLA₂α were prepared according to the standard protocol. The vectors for mutants cPLA₂α were prepared using a QuickChange kit (Stratagene, La Jolla, CA, USA) and respective primers. For instance, cPLA₂αS505A refers to the mutation of the Ser residue at position 505 to Ala in wild-type cPLA₂α. The primers for cPLA₂αS505A were CAC ATC ATA TCC ACT GGC TCC CCT GAG AGA GAC TTC AGC and its complement; for cPLA₂αS228A, they were CGT TGC TGG TCT TGC GGG CTC CAC CTG G and its complement. The entire coding regions of mutant cPLA₂α vectors were confirmed by DNA sequencing. The vectors for chimeric proteins containing green fluorescent protein (GFP) at the amino terminus of wild-type cPLA₂α and mutant cPLA₂α were prepared as previously reported (17). Transfection was performed with LipofectAMINE (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Transfection efficiencies were about 70–80% and 5–10% in the HEK293T cells and C12 cells transfected with pEGFP-CI-cPLA₂α, respectively, and 70–80% in the C12 cells transfected with pEB6 CAG-GFP.

C12 cells stably expressing wild-type cPLA₂α and mutant cPLA₂α were generated as previously described (17). Briefly, pcDNA4/HisMax-cPLA₂α and pPUR encoding the puromycin resistance gene (CLONTECH, Palo Alto, CA, USA) were transfected into C12 cells. Clones resistant to puromycin (10 μ g/mL, Sigma) were isolated by limiting dilution, tested for cPLA₂α expression, and maintained in the presence of puromycin. The expression of cPLA₂α was confirmed by immunoblotting using anti-cPLA₂α monoclonal antibody (4-4B-3C; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and by measurement of PLA₂ activity, as previously reported (19, 20). For immunoblotting, 30 μ g of protein per lane was applied to a sodium dodecyl sulfate-polyacrylamide gel for electrophoresis. The levels of β -tubulin in the respective samples from tested cells were almost the same. For the measurement of PLA₂ activity, 12.5 μ g of protein from cell lysate was used per tube. The values of cPLA₂ activity per tube were about 1500 dpm and 500 dpm in HEK293T and C12 cells expressing cPLA₂α, respectively, and 200–300 dpm in

control HEK293T cells and C12 cells transfected with the control vector.

AA release and PLA₂ activity

The release of AA from intact cells was determined as previously reported (10, 19). Briefly, cells (5×10^4) on 12-well plates were labeled overnight with $0.1 \mu\text{Ci}/\text{well}$ of [^3H]AA. Cells were washed three times with DMEM supplemented with 10 mM HEPES (pH 7.4) and 0.1% fatty acid-free bovine serum albumin (Sigma, A-7511). Cells were stimulated with $10 \mu\text{M}$ A23187 for 30 min, 100 nM PMA for 90 min, or 10 nM TNF α for 6 h at 37°C. In some experiments, cells were stimulated for the indicated time with the reagents. Then, the medium was collected and centrifuged at $8,000 \times g$ for 5 min. ^3H Radioactivity released into the supernatant was expressed as a percentage of the total incorporated radioactivity (20,000–40,000 dpm per well). cPLA₂ activity was measured using 1-palmitoyl-2-[^{14}C]-arachidonyl phosphatidylcholine as the substrate as previously described (19).

Confocal microscopy

The translocation of GFP-cPLA₂ α protein in cells was determined with a confocal laser scanning microscope (Olympus, Tokyo), as previously described (17).

Reverse transcription-polymerase chain reaction (RT-PCR) analysis

RT-PCR analysis was carried out as previously described (20). The primers for mouse TNF α receptors (p55 and p75) were described by Pan et al. (21).

Data presentation

Data concerning immunoblotting and confocal microscopy are from a typical experiment involving two or three independent experiments. For the measurement of AA release and PLA₂ activity, values are the mean \pm S.D. for three determinations in a typical experiment, and data are representative of three independent experiments. A statistical analysis for AA release was not performed, since the values were changeable depending on the individual experiment. The variation between each experiment was large and less than 50%.

Results

TNF α -, Ca²⁺ ionophore-, and PMA-induced AA release from L929 and C12 cells

C12 cells expressed undetectable levels of cPLA₂ α unlike the control L929 cells (Fig. 1, Panel A), as previously reported (2, 10). Addition of 10 nM TNF α markedly caused AA release for 6 h from L929 cells




Fig. 1. AA release induced by TNF α , A23187, and PMA in L929 and C12 cells. Soluble fractions from both L929 and C12 cells were analyzed by Western blotting using anti-cPLA₂ α antibody in Panel A. In Panel B, labeled L929 and C12 cells on dishes were incubated with 10 nM TNF α for 6 h, 10 μM A23187 for 30 min, or 100 nM PMA for 90 min. ^3H Contents in supernatants were calculated as percentages of the total incorporation of [^3H]AA. Data are the mean \pm S.D. of three determinations in a typical experiment involving three representative experiments.

(Panel B). No response to TNF α in L929 cells was detected in the period for 30 min–4 h after the addition under our conditions, as previously reported (3, 10). Thus, we measured AA release for 6 h induced by 10 nM TNF α in subsequent experiments. Addition of 30 and

100 nM TNFα caused significant AA release for 6 h from C12 cells in some experiments, although the response in C12 cells was much weaker than that in L929 cells. Addition of 10 μM A23187 caused AA release for 30 min in L929 cells. The AA release induced by A23187 from C12 cells was much weaker than that in L929 cells. Addition of 100 nM PMA, a direct activator of PKC, alone caused AA release for 90 min in L929 cells, but not in C12 cells. The effect of PMA on AA release for 30 min in L929 cells was marginal, but 100 nM PMA enhanced the A23187 (10 μM)-induced AA release for 30 min by about twofold; AA release was 1.9 (% of total) with vehicle, 1.6% with PMA alone, 3.7% with A23187 alone, and 6.7% with PMA plus A23187 in a typical experiment.

Expression of cPLA₂α in HEK293T and C12 cells using a transient expression system with pcDNA4/HisMax

First, we examined the effect of the vector pcDNA4/HisMax on the expression of cPLA₂α in HEK293T cells (Fig. 2, Panels A – C). cPLA₂α was expressed in native HEK293T cells, but at quite low levels. Transfection of HEK293T cells with the cPLA₂α expression vectors (wild-type, S228A, and S505A) caused a marked expression of cPLA₂α protein (Fig. 2, Panel A). The PLA₂ activity in the soluble fractions from HEK293T cells expressing wild-type cPLA₂α or cPLA₂αS505A was much stronger than that in the control cells (Panel B). The PLA₂ activity in HEK293T cells expressing cPLA₂αS228A was quite low, as previously reported (8). Next we investigated the effect of a Ca²⁺ ionophore (ionomycin) on the localization of GFP-cPLA₂α (Panel C). Stimulation of the cells with




Fig. 2. Expression of cPLA₂α in HEK293T and C12 cells induced by a transient expression system using pcDNA4/HisMax-cPLA₂α. In Panels A and B, HEK293T cells were transfected with pcDNA4/HisMax vector for wild-type cPLA₂α (WT) and mutant cPLA₂α. S228A and S505A are cPLA₂αS228A (mutation of Ser²²⁸ to Ala) and cPLA₂αS505A (mutation of Ser⁵⁰⁵ to Ala), respectively. cPLA₂α protein levels (Panel A) and the PLA₂ activity (Panel B) in the soluble fractions from respective cells were analyzed. In Panel C, HEK293T cells were transiently transfected with the expression vector for GFP-cPLA₂α, and translocation of GFP-cPLA₂α fusion protein induced by 5 μM ionomycin was measured before and after stimulation. In Panel D, C12 cells were transfected with the pcDNA4/HisMax expression vector for wild-type and mutant cPLA₂α. cPLA₂α protein levels in the soluble fractions from respective cells were analyzed. In Panel E, C12 cells were transiently transfected with the expression vector for GFP-cPLA₂α, and the translocation of GFP-cPLA₂α induced by 5 μM ionomycin was measured before and after stimulation.

5 μ M ionomycin triggered the translocation of GFP-cPLA₂ α to the perinuclear region within 1 to 2 min, as previously reported (9). Similarly, ionomycin triggered the translocation of GFP-cPLA₂ α S505A (data not shown), as previously reported (18). Stimulation with 100 nM PMA did not cause translocation 2 and 10 min after the addition (data not shown). Although cPLA₂ α was expressed in the transfected HEK293T cells and functional (enzyme activity and translocation), the addition of a Ca²⁺ ionophore (10 μ M A23187 and 5 μ M ionomycin) had a marginal or no effect on AA release from the cells (data not shown).

Transfection of C12 cells with these vectors caused little expression of wild-type cPLA₂ α and mutant-cPLA₂ α proteins (Fig. 2, Panel D). The application of 5 μ M ionomycin triggered the translocation of GFP-cPLA₂ α to the perinuclear region within 1 to 2 min in the GFP-positive cells (Panel E). The application of 10 μ M A23187 showed similar results (data not shown). Treatment with 10 nM TNF α for 6 h, 10 μ M A23187 for 30 min in the presence and absence of 100 nM PMA, and 100 nM PMA for 90 min did not stimulate AA release from these vector-transfected C12 cells (data not shown).

Expression of cPLA₂ α in C12 cells using pEB6 CAG

Next, we tried to express wild-type cPLA₂ α in C12 cells using the expression vector pEB6 CAG, which is useful for a relatively stable expression of proteins (22). In the conditions tested, transfection of C12 cells with pEB6 CAG-cPLA₂ α induced marked expression of cPLA₂ α protein (Fig. 3, Panel A). The release of AA induced by 10 μ M A23187 was greater in C12 cells expressing cPLA₂ α than in the native C12 cells or the control cells transfected with pEB6 CAG-GFP (Panel B). However, no TNF α -induced release was detected in C12 cells expressing cPLA₂ α .

AA release from stable clones of C12 cells expressing wild-type cPLA₂ α and cPLA₂ α S505A

We established two clones of C12 cells expressing wild-type cPLA₂ α and two clones of C12 cells expressing cPLA₂ α S505A (Fig. 4). Although the expression levels of cPLA₂ α were dependent on the respective clones, the protein levels of wild-type cPLA₂ α and cPLA₂ α S505A were much higher in these stable clones than in the control C12 cells (Panel A). The PLA₂ activity in the soluble fraction from C12 cell clones expressing wild-type cPLA₂ α and cPLA₂ α S505A was about twofold that in the control C12 cells and almost the same as that in L929 cells (data not shown). The reason for the inconsistency between cPLA₂ α protein levels and their enzyme activities is not clear at present.




Fig. 3. AA release in C12 cells transfected with pEB6 CAG-cPLA₂ α . C12 cells were transfected with the pEB6 CAG expression vector for GFP and wild-type cPLA₂ α (WT). cPLA₂ α levels in soluble fractions from the respective C12 cells are shown in Panel A. In Panel B, respective C12 cells were labeled with [³H]AA and then incubated with 10 nM TNF α or 10 μ M A23187 for 6 h and 30 min, respectively. Data are the mean \pm S.D. of three determinations in a typical experiment involving three representative experiments.

In a typical experiment (Panel B), the responses to A23187 were greater in C12 cells expressing wild-type cPLA₂ α and cPLA₂ α S505A than in the control C12 cells. Treatment with 100 nM PMA for 90 min caused AA release from C12 cells expressing wild-type cPLA₂ α and cPLA₂ α S505A, but not from control C12 cells. However, treatment with TNF α at 10 nM (Panel B) and 30 nM (data not shown) did not stimulate AA release for 6 h in the C12 cells expressing wild-type cPLA₂ α and cPLA₂ α S505A, as in the control C12 cells. In preliminary experiments, similar amounts of TNF α receptors (p55 and p75) transcripts were detected in L929 cells, C12 cells, and C12 cells expressing




Fig. 4. AA release from stable clones of C12 cells expressing wild-type and mutant cPLA₂α. WT-1 and WT-2 show two independent C12 cell clones expressing wild-type cPLA₂α, and S505A-1 and S505A-2 show two independent C12 cell clones expressing cPLA₂αS505A. The cPLA₂α levels in soluble fractions from the respective C12 cells are shown in Panel A. In Panel B, labeled C12 cells were incubated with 10 nM TNF α for 6 h, 10 μ M A23187 for 30 min, or 100 nM PMA for 90 min. Data are the mean \pm S.D. of three determinations in a typical experiment. The fold-increase in AA release induced by stimulants compared with that from the respective control cells is shown in parentheses.

wild-type cPLA₂α by RT-PCR analysis (data not shown). Figure 5 shows the responses to A23187 in other typical experiments (Panel A) and quantitative analyses of the A23187 responses in the respective cells (Panel B). The fold-increase induced by A23187 was significantly larger in the stable clones expressing




Fig. 5. A23187-induced AA release from stable clones of C12 cells expressing wild-type and mutant cPLA₂α. Labeled C12 cells were incubated with and without 10 μ M A23187 for 30 min. Panel A shows the data from two independent experiments, and the data are the mean \pm S.D. of three determinations in the respective experiments. ND, not determined. Panel B shows the results of the quantitative analyses of fold-stimulation induced by A23187 in the respective stable clones. Values are means \pm S.E.M. for four to six independent experiments. ^a $P < 0.05$, significantly different from the value in control cells.

wild-type cPLA₂α and cPLA₂αS505A than in the control cells. As in L929 cells, 100 nM PMA enhanced 10 μ M A23187-induced AA release for 30 min by about twofold in stable clones of C12 cells expressing wild-type cPLA₂α and cPLA₂αS505A (data not shown).

Discussion

Induced expression of cPLA₂α and its function in C12 cells

To investigate the regulatory mechanism of cPLA₂α

activation in cells, we tried to express wild-type and mutant cPLA₂α in a C12 cell clone, a L929 variant lacking cPLA₂α. On transient transfection using the pcDNA4/HisMax vector, cPLA₂α was expressed effectively in HEK293T cells but barely in C12 cells (Fig. 2). In the C12 cells treated with the pcDNA4/HisMax-cPLA₂α vector, no response was detected, probably because the percentage of transfected cells was quite low. However, the expressed cPLA₂α was translocated on stimulation with Ca²⁺ in the vector-transfected C12 cells (Fig. 2, Panel E). On transfection using the pEB6 CAG vector, cPLA₂α protein was effectively expressed and Ca²⁺, but not TNFα, stimulated AA release in the transfected C12 cells (Fig. 3). Further analysis of the release of AA in C12 cells transfected with pEB6 CAG-cPLA₂α was difficult since the response to Ca²⁺ was limited. Then, we established several stable clones of C12 cells expressing wild-type cPLA₂α and mutant cPLA₂α, and we found that they are useful for studying AA release responses.

In the present study, the Ca²⁺ ionophore-induced AA release was observed in stable C12 cell clones expressing wild-type cPLA₂α (and cPLA₂αS505A). PLA₂α activity increased in stable C12 cell clones expressing wild-type cPLA₂α (and cPLA₂αS505A). In addition, PMA-induced AA release was observed in stable C12 cell clones expressing cPLA₂α, like in L929 cells. These findings suggest that the cPLA₂α expressed in C12 cells is functionally active. Hayakawa et al. (10) reported that the release of AA induced by 300 ng/mL (about 18 nM) of TNFα for 2–4 h was observed in stable clones of C12 cells transfected with wild-type cPLA₂α cDNA. In our established C12 cell clones expressing wild-type cPLA₂α and cPLA₂αS505A, however, 10 and 30 nM TNFα did not stimulate AA release. Possible reasons for this discrepancy are discussed below.

Lack of TNFα-induced AA release from C12 cells expressing wild-type cPLA₂α

Inhibitors of transcription and translation acted synergistically with TNFα to cause the activation of cPLA₂ and/or release of AA in cells (23, 24). The absence of TNFα-induced AA release in C12 cells expressing cPLA₂α may be due to protein inhibitors that directly regulate cPLA₂α activity. PLA₂ activity in stable C12 cell clones expressing cPLA₂α was twofold higher than that in control C12 cells, but the activity was much lower than in HEK293T cells expressing cPLA₂α. However, the Ca²⁺ and PMA-evoked responses (cPLA₂α translocation and AA release) were observed in C12 cells with the expression of cPLA₂α. In a previous report by Hayakawa et al. (10), the sensitivity of

TNFα-induced cell death in C12 cell clones expressing cPLA₂, in which the PLA₂ activity was over 60% of that in the control L929 cells, was tenfold lower compared with that in L929 cells. Thus, molecules and/or processes that regulate the TNFα signaling pathway upstream from cPLA₂α may be modified in C12 cells, in addition to a lack of cPLA₂α.

TNFα elicits various biological effects as the result of complex signaling events that are initiated through polymerization of two distinct transmembrane receptors: TNFα receptor type 1 (p55) and type 2 (p75). Although L929 cells express both receptors (25, 26), cell death and/or apoptosis and NFκB activation induced by TNFα in L929 cells are mediated by p55 (25, 27). Human TNFα is shown to bind to mouse p55 but not to mouse p75, although human TNFα binds to both human receptors (28, 29). In the present study, we used human TNFα and the cells derived from mouse. Thus, AA release induced by TNFα from L929 cells is mediated by p55. Since C12 cells are analogous to L929 cells in TNFα receptor binding (1) and TNFα-induced activation of NFκB (3) and p55 transcripts were detected by RT-PCR analysis in native C12 cells and a stable clone of C12 cells expressing cPLA₂α, functions of TNFα receptor type 1 (p55) appeared to be intact in C12 cells.

It is reported that C12 cells expressed latent NFκB protein at twice the level of L929 cells (30), and the constitutive activity of superoxide dismutase in the TNFα-resistant subclone L929.12 was significantly greater than that in L929 cells (31). The TNFα-induced death of L929 cells is dependent on the production of reactive oxygen species (32, 33). Molecules in the TNFα signaling pathway such as TNFα receptor-associated factor 2 may be changed or the mechanisms keeping levels of reactive oxygen species low may exist in C12 cells. In addition, TNFα triggers the activation of phospholipase D 3–6 h after stimulation and concomitant phosphatidic acid production followed by a sustained diacylglycerol accumulation in human myeloblastic cells (34). Diacylglycerol acts through a variety of kinases including PKC and MAPK, and these kinases are able to phosphorylate and activate cPLA₂α (8, 9). The changes in levels of reactive oxygen species and diacylglycerol production induced by TNFα in both L929 and C12 cells should be determined. There is a need to identify the components necessary for TNFα-induced AA release in C12 cells, in addition to cPLA₂α.

No involvement of phosphorylation of cPLA₂α at Ser⁵⁰⁵ in PMA-induced AA release in intact cells

Activation of cPLA₂α is regulated by phosphorylation, in addition to Ca²⁺. Since Ser⁵⁰⁵ and Ser⁷²⁷ are

conserved among distinct species, these two amino acids appeared to regulate the activity in the presence of Ca²⁺ (8, 9). Ser⁵⁰⁵ is in the PXSP motif that represents a consensus MAPK phosphorylation site and phosphorylation of Ser⁵⁰⁵ in cPLA₂α increases the enzymatic activity probably by slowing the dissociation of membrane-bound cPLA₂α (18). Since the activation of PKC can trigger a kinase cascade leading to the activation of MAPK in cells, cPLA₂α activation and/or AA release by PMA appeared to be mediated at least partially through MAPKs including ERK1/2 (8, 15, 16). AA releases induced by A23187 with and without PMA from Chinese hamster ovary (CHO) cells expressing cPLA₂αS505A were significantly lower compared with those from CHO cells expressing wild-type cPLA₂α (14). In the present study, however, PMA stimulated AA release for 90 min and enhanced A23187-induced AA release for 30 min from C12 cells expressing cPLA₂αS505A, as it did from L929 cells and C12 cells expressing wild-type cPLA₂α. Thus, phosphorylation sites other than Ser⁵⁰⁵ in cPLA₂α are involved in the PMA-induced AA release from cells. Xu et al. (15) proposed that PKC activation stimulates two events in murine astrocytes; phosphorylation of cPLA₂α at a site(s) different from Ser⁵⁰⁵ through an ERK1/2-independent pathway and phosphorylation of cPLA₂α at Ser⁵⁰⁵ through an ERK1/2-dependent pathway. As previously proposed (35), the role of phosphorylation at Ser sites in the activation of cPLA₂α by protein kinases including PKC should be re-examined.

In conclusion, care should be taken when using a C12 cell clone as a cPLA₂α-deficient clone of L929 cells since C12 cells may lack components necessary for TNFα-induced AA release in addition to lacking cPLA₂α. PMA causes activation of cPLA₂α in a Ser⁵⁰⁵ phosphorylation-independent manner in C12 cells expressing cPLA₂α.

References

- Hayakawa M, Oku N, Takagi T, Hori T, Shibamoto S, Yamanaka Y, et al. Involvement of prostaglandin-producing pathway in the cytotoxic action of tumor necrosis factor. *Cell Struct Funct.* 1991;16:333–340.
- Enari M, Hug H, Hayakawa M, Ito F, Nishimura Y, Nagata S. Different apoptotic pathways mediated by Fas and the tumor necrosis-factor receptor. *Eur J Biochem.* 1996;236:533–538.
- Jayadev S, Hayter HL, Andrieu N, Gamard CJ, Liu B, Balu R, et al. Phospholipase A₂ is necessary for tumor necrosis factor α-induced ceramide generation in L929 cells. *J Biol Chem.* 1997;272:17196–17203.
- Lin Y, Choksi S, Shen HM, Yang QF, Hur GM, Kim YS, et al. Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation. *J Biol Chem.* 2004;279:10822–10828.
- Woo CH, Eom YW, Yoo MY, You HJ, Han HJ, Song WK, et al. Tumor necrosis factor-α generates reactive oxygen species via a cytosolic phospholipase A₂. *J Biol Chem.* 2000;275:32357–32362.
- Rogers RJ, Monnier JM, Nick HS. Tumor necrosis factor-α selectively induces *MnSOD* expression via mitochondria-to-nucleus signaling, whereas interleukin-1β utilizes an alternative pathway. *J Biol Chem.* 2001;276:20419–20427.
- Sánchez-Alcázar JA, Schneider E, Hernández-Muñoz I, Ruiz-Cabello J, Siles-Rivas E, de la Torre P, et al. Reactive oxygen species mediate the down-regulation of mitochondrial transcripts and proteins by tumor necrosis factor-α in L929 cells. *Biochem J.* 2003;370:609–619.
- Leslie CC. Properties and regulation of cytosolic phospholipase A₂. *J Biol Chem.* 1997;272:16709–16712.
- Hirabayashi T, Shimizu T. Localization and regulation of cytosolic phospholipase A₂. *Biochim Biophys Acta.* 2000;1488:124–138.
- Hayakawa M, Ishida N, Takeuchi K, Shibamoto S, Hori T, Oku N, et al. Arachidonic acid-selective cytosolic phospholipase A₂ is crucial in the cytotoxic action of tumor necrosis factor. *J Biol Chem.* 1993;268:11290–11295.
- Krönke M, Adam-Klages S. Role of caspases in TNF-mediated regulation of cPLA₂. *FEBS Lett.* 2002;531:18–22.
- Harper N, Hughes MA, Farrow SN, Cohen GM, MacFarlane M. Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling. *J Biol Chem.* 2003;278:44338–44347.
- Lin CC, Hsiao LD, Chien CS, Lee CW, Hsieh JT, Yang CM. Tumor necrosis factor-α-induced cyclooxygenase-2 expression in human tracheal smooth muscle cells: involvement of p42/p44 and p38 mitogen-activated protein kinases and nuclear factor-κB. *Cell Signal.* 2004;16:597–607.
- Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ. cPLA₂ is phosphorylated and activated by MAP kinase. *Cell.* 1993;72:269–278.
- Xu J, Weng YI, Simoni A, Krugh BW, Liao Z, Weisman GA, et al. Role of PKC and MAPK in cytosolic PLA₂ phosphorylation and arachidonic acid release in primary murine astrocytes. *J Neurochem.* 2002;83:259–270.
- Han WK, Sapirstein A, Hung CC, Alessandrini A, Bonventre JV. Cross-talk between cytosolic phospholipase A₂α (cPLA₂α) and secretory phospholipase A₂ (sPLA₂) in hydrogen peroxide-induced arachidonic acid release in murine mesangial cells. *J Biol Chem.* 2003;278:24153–24163.
- Hirabayashi T, Kume K, Hirose K, Yokomizo M, Iino M, Itoh H, et al. Critical duration of intracellular Ca²⁺ response required for continuous translocation and activation of cytosolic phospholipase A₂. *J Biol Chem.* 1999;274:5163–5169.
- Das S, Rafter JD, Kims KP, Gygi SP, Cho W. Mechanism of group IVA cytosolic phospholipase A₂ activation by phosphorylation. *J Biol Chem.* 2003;278:41431–41442.
- Nakamura H, Hirabayashi T, Someya A, Shimizu M, Murayama T. Inhibition of arachidonic acid release and cytosolic phospholipase A₂ activity by D-erythro-sphingosine. *Eur J Pharmacol.* 2004;484:9–17.
- Akiyama N, Hatori Y, Takashiro Y, Hirabayashi T, Saito T, Murayama T. Nerve growth factor-induced up-regulation of

- cytosolic phospholipase A₂ level in rat PC12 cells. *Neurosci Lett*. 2004;365:218–222.
- 21 Pan W, Csernus B, Kastin AJ. Upregulation of p55 and p75 receptors mediating TNF- α transport across the injured blood-spinal cord barrier. *J Mol Neurosci*. 2003;21:173–184.
 - 22 Tanaka J, Miwa Y, Miyoshi K, Ueno A, Inoue H. Construction of Epstein-Barr virus-based expression vector containing mini-oriP. *Biochem Biophys Res Commun*. 1999;264:938–943.
 - 23 Voelkel-Johnson C, Thorne TE, Laster SM. Susceptibility to TNF in the presence of inhibitors of transcription or translocation is dependent on the activity of cytosolic phospholipase A₂ in human melanoma tumor cells. *J Immunol*. 1996;156:201–207.
 - 24 Wu YL, Jiang XR, Newland AC, Kelsey SM. Failure to activate cytosolic phospholipase A₂ causes TNF resistance in human leukemic cells. *J Immunol*. 1998;160:5929–5935.
 - 25 Vercammen D, Vandenabeele P, Declercq W, Van de Craen M, Grooten J, Fiers W. Cytotoxicity in L929 murine fibrosarcoma cells after triggering of transfected human p75 tumor necrosis factor (TNF) receptor is mediated by endogenous murine TNF. *Cytokine*. 1995;7:463–470.
 - 26 Riffkin MC, Seow HF, Wood PR, Brown LE, Jackson DC, Scheerlinck JPY. *Trichostrongylus colubriformis* extract up-regulates TNF- α receptor expression and enhances TNF- α sensitivity of L929 cells. *Immunol Cell Biol*. 2000;78:575–579.
 - 27 Bulfone-Paus S, Bulanova E, Pohl T, Budagian V, Dürkop H, Rückert R, et al. Death deflected: IL-15 inhibits TNF- α -mediated apoptosis in fibroblasts by TRAF2 recruitment to the IL-15R α chain. *FASEB J*. 1999;13:1575–1585.
 - 28 Riches DWH, Chan ED, Zahradka EA, Winston BW, Remigio LK, Lake FR. Cooperative signaling by tumor necrosis factor receptors CD120a (p55) and CD120b (p75) in the expression of nitric oxide and inducible nitric oxide synthase by mouse macrophages. *J Biol Chem*. 1998;273:22800–22806.
 - 29 Doan JES, Windmiller DA, Eiches DWH. Differential regulation of TNF-R1 signaling: lipid raft dependency of p42^{mapk/erk2} activation, but not NF- κ B activation. *J Immunol*. 2004;172:7654–7660.
 - 30 Kitahara J, Sakamoto H, Tsujimoto M, Kanagawa Y. Involvement of NF- κ B in the protection of cell death by tumor necrosis factor in L929 derived TNF resistant C12 cells. *Biol Pharm Bull*. 2000;23:397–401.
 - 31 Polla BS, Jacquier-Sarlin MR, Kantengwa S, Mariethoz E, Hennet T, Russo-Marie F, et al. TNF α alters mitochondrial membrane potential in L929 but not in TNF α -resistant L929.12 cells: relationship with the expression of stress proteins, annexin 1 and superoxide dismutase activity. *Free Radic Res*. 1996;25:125–131.
 - 32 O'Donnell VB, Spycher S, Azzi A. Involvement of oxidants and oxidant-generating enzyme(s) in tumor-necrosis-factor- α -mediated apoptosis; role for lipoxygenase pathway but not mitochondrial respiratory chain. *Biochem J*. 1995;310:133–141.
 - 33 Hayter HL, Pettus BJ, Ito F, Obeid LM, Hannum YA. TNF α -induced glutathione depletion lies downstream of cPLA₂ in L929 cells. *FEBS Lett*. 2000;507:151–156.
 - 34 Plo I, Lautier D, Levade T, Sekouri H, Jaffrézou JP, Laurent G, et al. Phosphatidylcholine-specific phospholipase C and phospholipase D are respectively implicated in mitogen-activated protein kinase and nuclear factor κ B activation in tumor-necrosis-factor- α -treated immature acute-myeloid-leukemia cells. *Biochem J*. 2000;351:459–467.
 - 35 Hefner Y, Börsch-Haubold AG, Murakami M, Wilde JL, Pasquet S, Schieltz D, et al. Serine 727 phosphorylation and activation of cytosolic phospholipase A₂ by MNK1-related protein kinases. *J Biol Chem*. 2000;275:37542–37551.